Chemotherapy in metastatic renal cell carcinoma today? A systematic review

Anti-Cancer Drugs

Volumn 24, Issue 6, 2013, Pages 535-554

  Buti, Sebastiano ^a   Bersanelli, Melissa ^a   Sikokis, Angelica ^a   Maines, Francesca ^b   Facchinetti, Francesco ^a   Bria, Emilio ^b   Ardizzoni, Andrea ^a   Tortora, Giampaolo ^b   Massari, Francesco ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

antineoplastic combined chemotherapy protocols; chemotherapy; kidney cancer; metastatic renal cell carcinoma; renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; ETORICOXIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; INTERLEUKIN 2; IRINOTECAN; IXABEPILONE; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PIOGLITAZONE; REBECCAMYCIN; THALIDOMIDE; TROXACITABINE; VINBLASTINE; VINFLUNINE;

ALOPECIA; ANEMIA; ANOREXIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL RESEARCH; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; ERYTHEMA; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPONATREMIA; IMMUNOTHERAPY; INFECTION; KIDNEY DISEASE; KIDNEY METASTASIS; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; REVIEW; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CYTOKINES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS;

EID: 84878901004     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283609ec1     Document Type: Review

References (136)

1. LillebyW, Fossa SD. Chemotherapy in metastatic renal cell cancer. World J Urol 2005; 23:175-179. (Pubitemid 41136038)
2. Milowsky MI, Nanus DM. Chemotherapeutic strategies for renal cell carcinoma. Urol Clin North Am 2003; 30:601-609. (Pubitemid 37059565)
3. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-696.
4. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999; 353:14-17.
5. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26:5422-5428.
6. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28:2137-2143.
7. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370:2103-2111. (Pubitemid 350296300)
8. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28:2144-2150.
9. Motzer RJ, Hutson T, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. (Pubitemid 46089672)
10. Motzer RJ, Hutson T, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinb compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-3590.
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134. (Pubitemid 46089673)
12. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27:3312-3318.
13. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-1068.
14. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;4256-4265.
15. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281. (Pubitemid 46849157)
16. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794-5799.
17. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603.
18. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther 2011; 11:913-920.
19. Wenzel C, Locker GJ, Bartsch R, Pluschnig U, Mader R, Hussian D, et al. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Anticancer Drugs 2003; 14:779-784. (Pubitemid 38339781)
20. Petrioli R, Paolelli L, Francini E, Marsili S, Pascucci A, Sciandivasci A, et al. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. Anticancer Drugs 2007; 18: 817-820. (Pubitemid 46975968)
21. Tsimafeyeu I, Demidov L, Kharkevich G, Petenko N, Galchenko V, Sinelnikov I, Naidzionak U. Phase II, multicenter, uncontrolled trial of singleagent capecitabine in patients with non-clear cell metastatic renal cell carcinoma. Am J Clin Oncol 2012; 35:251-254.
22. Naito S, Eto M, Shinohara N, Tomita Y, Fujisawa M, Namiki M, et al. Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2010; 28: 5022-5029.
23. Townsley CA, Chi K, Ernst SD, Belanger K, Tannock I, Bjarnason GA, et al. National Cancer Institute of Canada-Clinical Trials Group. Phase II study of troxacitabine (BHC-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada- Clinical Trials Group. J Clin Oncol 2003; 21:1524-1529. (Pubitemid 46594105)
24. Hussain M, Vaishampayan U, Heilbrun LK, Jain V, LoRusso PM, Ivy P, Flaherty L. A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer. Invest New Drugs 2003; 21:465-471. (Pubitemid 38124987)
25. Thödtmann R, Sauter T, Weinknecht S, Weissbach L, Blatter J, Ohnmacht U, Hanauske A. A phase II trial of pemetrexed in patients with metastatic renal cancer. Invest New Drugs 2003; 21:353-358. (Pubitemid 37486336)
26. Fizazi K, Rolland F, Chevreau C, Droz JP, Mery-Mignard D, Culine S, Escudier B. A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer 2003; 98:61-65. (Pubitemid 36741126)
27. Goldstein D, Ackland SP, Bell DR, Olver IN, Davis ID, Rosenthal MA, et al. Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Invest New Drugs 2006; 24:429-434. (Pubitemid 43876079)
28. Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, et al. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010; 16:1634-1641.
29. Shamash J, Steele JP, Wilson P, Nystrom M, Ansell W, Oliver RT. IMP chemotherapy in cytokine refractory renal cell cancer. Br J Cancer 2003; 88:1516-1521. (Pubitemid 36713775)
30. Bennouna J, Delva R, Gomez F, Lesimple T, Geoffrois L, Linassier C, et al. A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma. Oncology 2003; 64:25-27. (Pubitemid 35477951)
31. Porta C, Zimatore M, Imarisio I, Natalizi A, Sartore-Bianchi A, Danova M, Riccardi A. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma. Cancer 2004; 100:2132-2138. (Pubitemid 38580331)
32. Haas NB, Giantonio BJ, Litwin S, Minniti CJ Jr, Fox S, Yeslow G, et al. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma. Cancer 2003; 98:1837-1841.
33. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003; 170: 1141-1145. (Pubitemid 37108098)
34. Waters JS, Moss C, Pyle L, James M, Hackett S, A'hern R, et al. Phase II clinical trial of capecitabine and gemcitabine in patients with metastatic renal carcinoma. Br J Cancer 2004; 91:1763-1768. (Pubitemid 39664962)
35. Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, et al. Cancer and Leukemia Group B. A phase II study of gemcitabine and capecitabine in metastatic renal cancer. Cancer 2006; 107:1273-1279.
36. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, et al. Capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008; 180:867-872.
37. Van Veldhuizen PJ, Hussey M, Lara PN Jr, Mack PC, Gandour-Edwards R, Clark JI, et al. A phase II study of gemcitabine and capecitabine in patients with advanced renal cell cancer. Am J Clin Oncol 2009; 32: 453-459.
38. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101:1545-1551. (Pubitemid 39318900)
39. Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer 2009; 7 (No 1):39-42.
40. Roubaud G, Gross-Goupil M, Wallerand H, de Clermont H, Dilhuydy MS, Ravaud A. Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma. Oncology 2011; 80 (3-4):214-218.
41. Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2011; 29:261-267.
42. Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, et al. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol 2012 [Epub ahead of print].
43. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22:1188-1194. (Pubitemid 41079830)
44. Atzpodien J, Kirchner H, Rebmann U, Soder M, Gertenbach U, Siebels M, et al. Interleukin-2/interferon-a2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2006; 95:463-469. (Pubitemid 44232555)
45. O'Brien MF, Rea D, Rogers E, Bredin H, Butler M, Grainger R, et al. Interleukin-2, interferon-a and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience. Eur Urol 2004; 45: 613-619. (Pubitemid 38481689)
46. Gez E, Rubinov R, Gaitini D, Meretyk S, Best LA, Mashiach T, et al. Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the Rambam and Linn medical centers, Haifa, Israel. J Chemother 2007; 19:79-84.
47. Buti S, Brighenti M, Bongiovanni C, Buzio C, Chiesa MD, Alberici F, Passalacqua R. Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC). J Immunother 2007; 30:780-786. (Pubitemid 47480761)
48. Westermann J, Hecker AC, Florcken A, Dorken B, Pezzutto A. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus a-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer. J Immunother 2009; 32:667-675.
49. Rathmell KW, Malkowicz SB, Holroyde C, Luginbuhl W, Vaughn DJ. Phase II trial of 5-fluorouracil and leucovorn in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. Am J Clin Oncol 2004; 27:109-112. (Pubitemid 38451470)
50. Amato JR, Rawat A. Interferon-a plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study. Invest New Drugs 2006; 24:171-175. (Pubitemid 43723892)
51. Segota E, Mekhail T, Olencki T, Hutson TE, Dreicer R, Wacker B, et al. Phase II trial of capecitabine and rHu-interferon-a-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. Urol Oncol 2007; 25:46-52. (Pubitemid 46027613)
52. Padrik P, Leppik K, Arak A. Combination therapy with capecitabine and interferon alfa-2a in patients with advanced renal cell carcinoma: a phase II study. Urol Oncol 2004; 22:387-392.
53. Ravaud A, Trufflandier N, Ferriè re JM, Debled M, Palussiè re J, Cany L, et al. Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. Br J Cancer 2003; 89: 2213-2218. (Pubitemid 38168002)
54. Sunela KL, Koskinen S, Kellokumpu-Lehtinen PL. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer. Cancer Chemother Pharmacol 2010; 66:59-67.
55. Walter B, Schrettenbrunner I, Vogelhuber M, Grassinger J, Bross K,Wilke J, et al. Pioglitazone, etoricoxib, interferon-a, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. Med Oncol 2012; 29:799-805.
56. Mencoboni MP, Tredici S, Varaldo M, Queirolo G, Durand F, Rebella L, et al. Chemoimmunotherapy with low dose vinorelbine and interleukin-2 in treatment of patients with metastatic renal cell carcinoma. Neoplasma 2006; 53:333-336. (Pubitemid 44105940)
57. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342. (Pubitemid 38702844)
58. Reck M, Von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first line therapy for non-squamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
59. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
60. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27:4966-4972.
61. Perren T, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. ICON7: a phase III gynaecologic cancer intergroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer [abstract LBA4]. Ann Oncol 2010; 21 (Suppl):8.
62. Jain R. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62. (Pubitemid 40093472)
63. Carbonaro M, Escuin D, O'Brate A, Thadani-Mulero M, Giannakakou P. Microtubules regulate hypoxia-inducible factor-1a protein trafficking and activity: implications for taxane therapy. J Biol Chem 2012; 287: 11859-11869.
64. Pu YS, Huang CY, Chen JY, Kang WY, Lin YC, Shiu YS, et al. Downregulation of PKCzeta in renal cell carcinoma and its clinicopathological implications. J Biomed Sci 2012; 19:39-49.
65. Zhu H, Wang Z, Xu Q, Zhang Y, Zhai Y, Bai J, et al. Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy. Cancer Biol Ther 2012; 13:13-18.
66. Vasko R, Mueller GA, von Jaschke AK, Asif AR, Dihazi H. Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis. Eur J Pharmacol 2011; 670:50-57.
67. Doberstein K, Wieland A, Lee SB, Blaheta RA, Wedel S, Moch H, et al. L1-CAM expression in ccRCC correlates with shorter patient survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis 2011; 32:262-270.
68. Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, OoiW, et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol 2009; 9:6.
69. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 2009; 69:9056-9064.
70. Sato H, Senba H, Virgona N, Fukumoto K, Ishida T, Hagiwara H, et al. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells. Mol Carcinog 2007; 46:215-224. (Pubitemid 46399520)
71. Kausch I, Jiang H, Thode B, Doehn C, Krüger S, Jocham D. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma. Eur Urol 2005; 47:703-709. (Pubitemid 40521925)
72. Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, et al. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res 2002; 22 (1A):121-128. (Pubitemid 34475285)
73. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001; 3:360-367. (Pubitemid 32801886)
74. KimWJ, Kakehi Y, Kinoshita H, Arao S, Fukumoto M, Yoshida O. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J Urol 1996; 156 (Pt 1):506-511. (Pubitemid 126445369)
75. Mickisch GH, Noordzij MA, vd Gaast A, Gebreamlack P, Köhrmann KU, Mogler-Drautz E, et al. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 1995; 121 (Suppl 3):R11-R16. (Pubitemid 26253215)
76. Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O'Brien JP. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995; 13:1958-1965.
77. Volm M, Kästel M, Mattern J, Efferth T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 1993; 71:3981-3987. (Pubitemid 23172981)
78. Mickisch GH. Chemoresistance of renal cell carcinoma: 1986-1994. World J Urol 1994; 12:214-223.
79. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281. (Pubitemid 28342121)
80. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukine-2 or high-dose interleukine-2 alone. N Engl J Med 1987; 316:898-905.
81. Tourani JM, Lucas V, Mayeur D, Dufour B, DiPalma M, Boaziz C, et al. Subcutaneous recombinant interleukin-2 (rIL-2) in outpatient treatment with metastatic renal cell carcinoma. Results of a multicenter SCAPP trial. Ann Oncol 1996; 7:525-528. (Pubitemid 26232961)
82. World Health Organization. WHO handbook for reporting results of cancer treatment, WHO publication 48. Geneva, WHO; 1979.
83. Bergman AM, Pinedo hM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL, Peters GJ. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated proteinoverexpressing human cancer cell lines. Br J Cancer 2003; 88:1963-1970. (Pubitemid 36829675)
84. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540. (Pubitemid 29368255)
85. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan RM. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43- 9006) in patients with advanced renal cell carcinoma [abstract 794]. Eur J Cancer Suppl 2005; 3:226.
86. Motzer RJ, Michaelson MD, Redman BG, Hudes GR,Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24. (Pubitemid 46630489)
87. Sanchez P, Calvo E, Duran I. Non-clear cell advanced kidney cancer: is there a gold standard? Anticancer Drugs 2011; 22 (Suppl 1):S9-S14.
88. David KA, Milowsky MI, Nanus DM. Chemotherapy for non-clear-cell renal cell carcinoma. Clin Genitourin Cancer 2006; 4:263-268. (Pubitemid 43779883)
89. Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004; 28:435-441. (Pubitemid 38436516)
90. De Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001; 25:275-284. (Pubitemid 32174196)
91. Dutcher JP, Nanus DM. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2011; 28: 1530-1533.
92. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, et al. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer 2012; 1:8-22.
93. Umeda T, Niijima T. Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer 1986; 58: 1231-1235.
94. Von der Maase H, Geertsen P, Tatcher N, Jasmin C, Mercatello A, Fossa SD, et al. Recombinant interleukin-2 in metastatic renal cell carcinoma - a European multicentre phase II study. Eur J Cancer 1991; 27:1583-1589.
95. Cameron RB, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 1988; 58:5810-5817.
96. Rini BI, Vogelzang NJ, Dumas MC, et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000; 18:2419-2426. (Pubitemid 30415829)
97. George S, Dreicer R, Au JL, Shen T, Rini BI, Roman S, et al. Phase I/II trial of 5-fluorouracil and noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2008; 6:79-85.
98. Stadler WM, Desai AA, Quinn DI, Bukowski R, Poiesz B, Kardinal CG, et al. A phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol 2008; 61:689-694.
99. Bellmunt J, Trigo JM, Calvo E, Carles J, Pé rez-Gracia JL, Rubió J, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010; 11:350-357.
100. Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M, et al. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res 2010; 14:287-291.
101. Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, et al. Treatment of metastatic renal cell carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int 2010; 107:741-748.
102. Pacheco AV, Rasila K, Lee SJ, Rabinowitz I, Elias L, Lee FC, Verschraegen CF. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. Urol Oncol 2007; 26:610-615.
103. Buti S, Lazzarelli S, Chiesa MD, Simonelli C, Re GL, Lheshi A, et al. Dose finding trial of a combined regimen with bevacizumab, immunotherapy and chemotherapy in patients with metastatic renal cell cancer: an Italian Oncology Group for Clinical Research (GOIRC) study. J Immunother 2010; 33:735-741.
104. Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 2004; 10:4724-4733. (Pubitemid 38955523)
105. Rini BI, Flaherty K. Clinical effect and future considerations for molecularlytargeted therapy in renal cell carcinoma. Urol Oncol 2008; 26:543-549.
106. Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol 2003; 44:65-75. (Pubitemid 36741377)
107. Berg WJ, Divgi CR, Nanus DM, Motzer RJ. Novel investigative approaches for advanced renal cell carcinoma. Semin Oncol 2000; 27:234-239. (Pubitemid 30205378)
108. Huang A, Fan H, Taylor WR,Wright JA. Ribonuclotide reductase R2 gene expression and changes in drug sensitivity and genome stability. Cancer Res 1997; 57:4876-4881. (Pubitemid 27468997)
109. Au JL, Rustum YM, Ledesma EJ, Mittelman A, Creaven PJ. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res 1982; 42:2930-2937. (Pubitemid 12085770)
110. Leonard GD, Polgar O, Bates SE. ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 2002; 3:1652-1659. (Pubitemid 36266743)
111. Huijts CM, Santegoets SJ, van den Eertwegh AJ, Pijpers LS, Haanen JB, de Gruijl TD, et al. Phase I-II study of everolimus and low dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer 2011; 11:505.
112. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434. (Pubitemid 36910021)
113. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918. (Pubitemid 41103603)
114. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-2512. (Pubitemid 46630627)
115. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25:4536-4541. (Pubitemid 350035309)
116. Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P, et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008; 26:2285-2291.
117. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28:475-480.
118. Jonasch E, Corn P, Pagliaro LC,Warneke CL, Johnson MM, Tamboli P, et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and lowdose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010; 116:57-65.
119. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010; 16:5539-5547.
120. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931-1939.
121. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, et al. Sorafenib with interleukin-2 vs. sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 2011; 104:1256-1261.
122. Né grier S, Gravis G, Pé rol D, Chevreau C, Delva R, Bay JO, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011; 12:673-680.
123. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012; 30:1371-1377.
124. Nosov DA, Esteves B, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 2012; 30:1678-1685.
125. Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer 2012; 48:527-537.
126. Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebocontrolled, phase 2 study. Cancer 2012; 118:6152-6161.
127. Bracarda S, Porta C, Boni C, Santoro A, Mucciarini C, Pazzola A, et al. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). Eur Urol 2013; 63:254-261.
128. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127-131.
129. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10:757-763.
130. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116:1272-1280.
131. Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology 2011; 80 (5-6):395-405.
132. Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EUARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011; 22:1812-1823.
133. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, et al. REACT Study Group. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer 2012; 48:324-332.
134. Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, et al. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. Cancer Immunol Immunother 2010; 59:553-561.
135. Porta C, Procopio G, Cartení G, Sabbatini R, Bearz A, Chiappino I, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011; 108 (Pt 2):E250-E257.
136. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 2011; 22:1048-1053.